Company Prevail Therapeutics Inc.
Equities
PRVL
US74140Y1010
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Franz Hefti
CEO | Chief Executive Officer | 76 | 28/02/18 |
Jeffrey Sevigny
CTO | Chief Tech/Sci/R&D Officer | 55 | 28/02/18 |
Emily Minkow
PRN | Corporate Officer/Principal | 41 | 31/10/18 |
Yong Dai
PRN | Corporate Officer/Principal | 53 | 31/01/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 34,248,033 | 29,795,530 ( 87.00 %) | 0 | 87.00 % |
Company contact information
Prevail Therapeutics, Inc.
430 East 29th Street Suite 1520
10016, New York
+
http://www.prevailtherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
-1.36% | 104B | |
+5.12% | 97.47B | |
+5.71% | 22.25B | |
-13.52% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-11.00% | 16.36B | |
+8.73% | 14.39B | |
+40.39% | 12.37B |